(Press-News.org) An SGH study has revealed that considering all osteoporotic patients as having simple osteoporosis and treating all of them alike by putting them on potent long term medication without finding out the cause of their osteoporosis may be ineffective and in most cases downright harmful.
Secondary osteoporosis is a rather common but lesser known type of osteoporosis that affects men and women of any age. It is caused by certain medical conditions that result in bone loss or interfere with development of peak bone mass. Contributors of secondary osteoporosis include conditions such as hypercalciuria, hyperthyroidism, hyperparathyroidism, vitamin D deficiency and hypogonadism. The study is the first of its kind in South East Asia.
To find out how common these secondary osteoporosis contributors are in our population, a team led by Dr Manju Chandran, Programme Director, Osteoporosis and Bone Metabolism Unit at SGH, evaluated 400 patients over two years. The study found that almost half of the patients with osteoporosis had one or more secondary contributors. Secondary osteoporosis, if not identified and treated, can lead to devastating consequences both in terms of fractures as well as from the disease that caused the osteoporosis in the first place.
Conditions that contribute to secondary osteoporosis may not be obvious without detailed history taking and laboratory testing. The study revealed that 22 per cent of the patients with a secondary cause had increased calcium excretion in the urine, which in most cases could be attributed to a high salt diet. Another 18.5 per cent had vitamin D deficiency, 10.1 per cent had hyperthyroidism and nearly 10 per cent of the men had hypogonadism or low sex hormone levels.
"In our study, the prevalence of secondary osteoporosis in men was found to be high, almost 63 per cent. Our recommendation is for all men with osteoporosis to have some basic laboratory testing to look at their levels of male hormone, urine calcium, vitamin D, thyroid function, etc.," said Dr Chandran, who is also Consultant, Department of Endocrinology, SGH and President, Endocrine and Metabolic Society of Singapore.
"For post-menopausal women, laboratory testing may not be feasible or cost effective as post-menopausal osteoporosis is very common. However, directed testing based on their bone mineral density loss can be done to determine the appropriate treatment for these patients. The appropriate treatment for secondary osteoporosis is treating the condition, which caused it in the first place and not antiosteoporosis medicines," Dr Chandran added.
It is estimated that about 55,000 to 60,000 female Singaporeans above the age of 50 suffer from osteoporosis and that excludes men who are also hit by the disease. While secondary osteoporosis may not be completely reversible, the right treatment can halt the progress of bone loss and prevent excessive fracturing and in some cases even save the life of the patient.
### END
Secondary osteoporosis: More than what meets the eye!
2012-10-09
ELSE PRESS RELEASES FROM THIS DATE:
Coffee speeds up return of bowel function after colon surgery
2012-10-09
Patients who drank coffee, rather than water, after bowel surgery to remove a part of their colon experienced a quicker return to bowel movements and tolerance of solid food.
Those are two of the key findings of a comparative study of 80 patients, carried out at University Hospital Heidelberg, Germany, and published in the surgical journal BJS.
"Post-operative bowel obstruction is a common problem after abdominal surgery and the aim of this study was to test our theory that coffee would help to alleviate this" says lead author Dr Sascha Müller, who is now based at ...
Glowing DNA invention points towards high speed disease detection
2012-10-09
Links to publications:
http://pubs.acs.org/doi/abs/10.1021/nn302633q
http://pubs.acs.org/doi/abs/10.1021/ac201903n
...
Mayo Clinic researchers stop neuromyelitis optica attacks with new therapy
2012-10-09
ROCHESTER, Minn. -- Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS). In the study, patients with severe symptoms of the disease, also known as NMO, were given eculizumab, a drug typically used to treat blood disorders.
While not a cure, the therapy Mayo Clinic researchers used in the study to halt attacks could potentially lead to longer attack-free ...
Dead stars could be the future of spacecraft navigation
2012-10-09
Scientists at the National Physical Laboratory (NPL) and the University of Leicester have been commissioned by the European Space Agency (ESA) to investigate the feasibility of using dead stars to navigate spacecraft in deep space. The findings of the research will advise ESA strategy and if feasible this technique may in future revolutionise the way spacecraft navigate in the outer Solar System and beyond.
Spacecraft navigation currently relies on radio transmissions between a distant craft and a network of ground-stations on Earth. This means that the craft has to ...
IspH -- a protein free to choose its partners
2012-10-09
This press release is available in German.
The iron-sulfur protein IspH plays a central role in the terpene metabolism of several pathogens. The mechanism of the reaction provides an approach for developing new antibiotics, particularly against malaria and tuberculosis. While researching this enzyme, biochemists at the Technische Universitat Munchen discovered a previously unknown reaction: IspH accepts two completely different classes of molecules as partners. This surprising insight, published in Nature Communications, opens up new perspectives in combating infectious ...
Scientists discover gene behind rare disorders
2012-10-09
Scientists at the Montreal Neurological Institute and Hospital – The Neuro, McGill University working with a team at Oxford University have uncovered the genetic defect underlying a group of rare genetic disorders.
Using a new technique that has revolutionized genetic studies, the teams determined that mutations in the RMND1 gene were responsible for severe neurodegenerative disorders, in two infants, ultimately leading to their early death. Although the teams' investigations dealt with an infant, their discovery also has implications for understanding the causes of ...
Chaperone protein subverts removal of glaucoma-causing protein
2012-10-09
Tampa, FL (Oct. 8, 2012) -- The chaperone protein Grp94 can interfere with the clearance of another protein known to cause the glaucoma when mutated, a new study led by researchers at the University of South Florida has found. Using a cell model, the researchers also demonstrated that a new specific inhibitor of Grp94 facilitates clearance of the genetically-defective protein, called myocilin, from cells.
Reported online this month in JBC (The Journal of Biological Chemistry), the discoveries could lead to a new treatment for some hereditary cases of glaucoma, an eye ...
Topological superconductors
2012-10-09
If quantum computers are ever going to perform all those expected feats of code-breaking and number crunching, then their component qubits---tiny ephemeral quantum cells held in a superposition of internal states---will have to be protected from intervention by the outside world. In other words, decoherence, the loss of the qubits' quantum integrity, has to be postponed. Now theoretical physicists at the Joint Quantum Institute (JQI) and the University of Maryland have done an important step forward to understand qubits in a real-world setup. In a new study they show, ...
Bioenergy - The broken promise
2012-10-09
Biofuels are going to save us from climate threats and the oil crisis, while at the same time providing an opportunity to the smallholder farmers of the world. Hopes are high, but completely unrealistic. It is like trying to push a square peg into a round hole, according to a current thesis at Linköping University.
Bioenergy could replace fossil fuels and solve the looming energy crisis. Into the bargain, we will benefit from reduced greenhouse gas emissions. A further bonus could be that demand for biofuels gives a lift to smallholder farmers in poor countries, who would ...
Doubling up on advanced prostate cancer with PARP inhibitors
2012-10-09
A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.
The team, led by Karen E. Knudsen, Ph.D., Professor in the Departments of Cancer Biology, Urology, & Radiation Oncology at Thomas Jefferson University, found that functions of PARP-1 not only include DNA damage repair but also androgen receptor (AR) regulation in advanced prostate cancer growth and progression. PARP inhibition ...